Plenary Session 2: Systematic Functional Genomics I
8:00 a.m.-10:00 a.m.
Functional genomics and synthetic lethality
William C. Hahn, Dana-Farber Cancer Institute, Boston, MA
Non-oncogene addiction in multiple myeloma
Louis M. Staudt, National Cancer Institute, Bethesda, MD
Chromosome instability and synthetic lethality in yeast and cancer
Philip Hieter, University of British Columbia, Vancouver, BC, Canada
Functional characterization of breast cancer using pooled lentivirus shRNA screens*
Richard Marcotte, Ontario Cancer Institute, University Health Network, Toronto, ON, Canada
Targeting altered SWI/SNF function through synthetic lethal RNAi screening*
Andrew R. Conery, Constellation Pharmaceuticals, Inc., Cambridge, MA
|
Plenary Session 3: New Technology and Bioinformatics I
10:30 a.m.-12:30 p.m.
Haploid genetic screens in human cells
Thijn Brummelkamp, Netherlands Cancer Institute, Amsterdam, The Netherlands
Systematic mapping of cancer drug resistance mechanisms through high-density genetic interaction maps
Jonathan Weissman, University of California, San Francisco, CA
Targeting intratumoral genetic heterogeneity through rationally designed combination therapy
Douglas A. Lauffenburger, Massachusetts Institute of Technology, Cambridge, MA
Genome-wide screens for Wnt signaling in human haploid cells*
Andres Lebensohn, Stanford University, Stanford, CA
A network-based approach for drug synergy prediction from gene expression data*
Mariano J. Alvarez, Columbia University, New York, NY
|
Plenary Session 4: Systematic Functional Genomics II
3:00 p.m.-5:00 p.m.
Identification of therapeutic targets for MYC-driven cancers by functional genomics
Carla Grandori, Fred Hutchinson Cancer Research Center, Seattle, WA
Functional genomics of breast cancer
Benjamin G. Neel, University of Toronto Ontario Cancer Institute, Toronto, ON, Canada
Targeting the dependence of N-Myc on interaction with Aurora-A with small molecules
Martin Eilers, University of Würzburg, Würzburg, Germany
Construction of synthetic lethal networks for p53 tumor suppressor pathways identifies candidate therapeutic targets for metastatic chemotherapy-resistant HNSCC*
Chris Kemp, Fred Hutchinson Cancer Research Center, Seattle, WA
Systematic genetic interaction maps reveal synthetic-lethal vulnerabilities in leukemia and multiple myeloma*
Martin Kampmann, University of California, San Francisco/HHMI, San Francisco, CA
|